• Publications
  • Influence
High functional levels of thrombin‐activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke
Summary.  Background and objective: Several studies have suggested that thrombin‐activatable fibrinolysis inhibitor (TAFI) levels are associated with the risk of arterial thrombosis, but results haveExpand
  • 101
  • 3
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study
Background Optimal antithrombotic treatment after transcatheter aortic valve replacement (TAVR) is unknown and determined empirically. The direct factor Xa inhibitor rivaroxaban may potentiallyExpand
  • 73
  • 3
  • PDF
TAFI and Pancreatic Carboxypeptidase B Modulate In Vitro Capillary Tube Formation by Human Microvascular Endothelial Cells
Objective— Besides having a key role in fibrinolysis, the plasminogen system has been implicated in cell migration and angiogenesis. A common mechanism is the binding of plasminogen toExpand
  • 29
  • 2
Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis
TAFIa was shown to attenuate fibrinolysis. In our in vitro study, we investigated how the inhibitory effect of TAFIa depended on the type and concentration of the plasminogen activator (PA). WeExpand
  • 19
  • 2
  • PDF
Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children
Summary.  Background and objectives: In pediatric meningococcal sepsis, an imbalance between coagulation and fibrinolysis and proinflammatory action play major roles. We hypothesized that thrombinExpand
  • 32
  • 1
A new functional assay of thrombin activatable fibrinolysis inhibitor
Summary.  New thrombin activatable fibrinolysis inhibitor (TAFI) assays are necessary for studying the role of this fibrinolysis inhibitor in cardiovascular disease. The identification of aExpand
  • 24
  • 1
The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study 1
Summary.  Background and objectives: Thrombin activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis and may therefore contribute to the pathophysiology of arterial thrombosis. The aim ofExpand
  • 61
Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI).
In this study, the in-vitro fibrinolytic efficacy of Tenecteplase, Amediplase and scu-PA was investigated in different external lysis models by measuring the lysis of human plasma clots after theExpand
  • 14
Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children
Summary. Background and objectives: In pediatric meningococcal sepsis, an imbalance between coagulation and fibrinolysis and proinflammatory action play major roles. We hypothesized that thrombinExpand
  • 17
High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease.
BACKGROUND Previous studies suggested that hypofibrinolysis is associated with increased risk of peripheral arterial disease. Thrombin activatable fibrinolysis inhibitor (TAFI) has been identified asExpand
  • 16
  • PDF